Last reviewed · How we verify

Digestive Care, Inc. — Portfolio Competitive Intelligence Brief

Digestive Care, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PANCRECARB® (pancrelipase) PANCRECARB® (pancrelipase) phase 3 Pancreatic enzyme replacement therapy Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abbott · 1 shared drug class
  2. Asian Institute of Gastroenterology, India · 1 shared drug class
  3. Foundation for Liver Research · 1 shared drug class
  4. Hospital Clinico Universitario de Santiago · 1 shared drug class
  5. Ohio State University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Digestive Care, Inc.:

Cite this brief

Drug Landscape (2026). Digestive Care, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/digestive-care-inc. Accessed 2026-05-18.

Related